cyclosporine

We found clinical, histological, and molecular evidence demonstrating the efficacy of cyclosporine in reducing the expanded malignant clone and achieving durable clinical remission for more than a year. Our findings highlight the complex interplay between CAR T-cell therapy, pre-existing genetic vulnerabilities, and the GI microenvironment, emphasizing the need for vigilant monitoring and tailored therapeutic strategies to address the risks associated with CAR-T lymphomagenesis.

She received granulocyte colony-stimulating factor (GCSF), thrombopoietin (TPO) mimetic, and immunosuppressive therapy with prednisone prior to primary cytoreductive surgery to no apparent gross residual disease...She was treated with anti-thymocyte globulin (ATG) and cyclosporine and subsequently received adjuvant chemotherapy with weekly cisplatin and subsequent addition of weekly paclitaxel, resulting in reduction in her serum Cancer Antigen-125 (CA-125) and no radiographic evidence of disease. Despite initial response, her clinical deterioration and her decision to forego further cancer- or aplastic anemia-directed therapy resulted in transition to home hospice care, and she was discharged 119 days after admission. This case report highlights the importance of multi-disciplinary collaboration to manage the medical complexities of paraneoplastic aplastic anemia secondary to a gynecologic malignancy.

P2, N=135, Active, not recruiting, BioRay Pharmaceutical Co., Ltd. | Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> May 2027 | Trial primary completion date: Dec 2027 --> Mar 2027

Molecular docking and dynamics simulations revealed valproic acid, cyclosporine, and genistein as potential therapeutic compounds with strong binding affinities to the hub genes...This comprehensive study highlights the potential of ULBP2, INHBB, and STC2 as promising biomarkers for CRC, emphasizing their roles in regulating tumor progression and immune responses. Future studies should focus on targeted therapeutic strategies that utilize these biomarkers to enhance treatment efficacy and patient prognosis.

The patient had previously received adjuvant oral tegafur-uracil for 2 years without any hematologic toxicity...Treatment with cyclosporine led to gradual hematologic improvement and transfusion independence. This is a rare case of osimertinib-induced aplastic anemia occurring after curative-intent surgery for NSCLC, in contrast to previously published reports that mainly involved patients with advanced or metastatic disease. Clinicians should be aware of this rare but life-threatening complication and closely monitor peripheral blood counts during treatment, particularly within the first 2-8 months after treatment initiation.

The SA-GA conjugate was employed to formulate SLNs using a hot homogenization-ultrasonication-solvent evaporation technique for the peroral delivery of cyclosporine (CsA), paclitaxel (PTX), and urolithin-A (UA). Further, in cisplatin-induced HK2 cell damage models, UA-loaded SA-GA SLNs significantly reduced inflammatory markers TLR4, NF-κB, and IL-1β. These results highlight UA-loaded SA-GA SLNs as a promising TfR-targeted oral delivery system for mitigating cisplatin-induced acute kidney injury (AKI) in cancer therapy.

Emerging biologics have significantly advanced the management of PsA, offering greater efficacy and safety compared to conventional DMARDs. IL-17 and IL-23 inhibitors, along with newer agents like bimekizumab, present promising treatment options for patients with inadequate responses to TNF inhibitors. Personalized treatment strategies, based on disease phenotype and individual patient needs, are essential for optimizing outcomes in PsA management. Further research into long-term efficacy and safety is required to refine treatment protocols and improve patient outcomes.

To conclude, local experience suggested that the modified 1-day reduced-intensity regimen in combination with fresh but not cryopreserved PBSC graft is feasible and promising to achieve sustained engraftment. It is a safe and appropriate approach in salvaging paediatric patients with graft failure requiring immediate re-transplantation.

P4, N=32, Not yet recruiting, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi

All patients received an identical conditioning regimen with different GVHD prophylaxis: sirolimus + mycophenolate mofetil (MMF) or cyclosporine + MMF. Our results suggest that the daily administration and dosing used for GVHD prevention are less likely to confer clinical benefits, possibly indicating that the beneficial effects of sirolimus occur within a specific therapeutic window. These findings highlight the need to further investigate senotherapeutic approaches in this setting of accelerated aging.

By October 2024, clinical decline with cutaneous ulcers and severe lymphopenia prompted cyclosporine (CyA) initiation...A multidisciplinary team approved the escalation to rituximab, which, in combination with her existing regimen, led to clinical stabilization and the resolution of her pulmonary and cutaneous symptoms. This case emphasizes the complexity of managing anti-MDA5-positive DM with severe pulmonary complications. Early recognition, a multidisciplinary approach, and personalized treatment are crucial to improving outcomes.

P3, N=53, Active, not recruiting, Boston Children's Hospital | Recruiting --> Active, not recruiting | N=234 --> 53